ArticleScientific reports2025
The value of MRI-based radiomics and clinicoradiological data for the detection of forkhead box protein A1 gene mutated prostate cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to develop models for predicting forkhead box protein A1 (FOXA1) gene mutations in prostate cancer using clinicoradiological and MRI radiomics data. Totally 367 prostate cancer patients (109 with FOXA1 mutations and 258 without) from three centers underwent multiparametric MRI. Patients from Center 1 (n = 236) were randomly divided into training and internal validation sets (7:3). Patients from Centers 2 and 3 (n = 131) were used for external validation. The index tumor lesion's volume of interest was delineated on MRI images to obtain 428 radiomics features for each patient. Radiomics features were selected by least absolute shrinkage and selection operator regression. Clinicoradiological features were compared between mutant and wild-type patients for feature selection. Those selected features were further chosen by binary logistic regression (LR) analysis, and used to develop prediction models for FOXA1 mutations with LR, support vector machine (SVM), and random forest (RF) classifiers. Models' performances were assessed by area under the receiver operating characteristic curve (AUC). No clinicoradiological feature was associated with FOXA1 mutations, while three radiomics features were selected to build models. AUCs of RF model in internal and external validation sets (0.82 and 0.81) were significantly greater than LR (0.74 and 0.71) and SVM (0.60 and 0.65) models (all p < 0.05), while AUC of LR model was greater than SVM model in internal validation set (p = 0.03). Radiomics method with RF classifier could effectively predict FOXA1 mutations in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.